UNICREDIT BANK/CALL/MODERNA/250/0.1/18.06.25 | Real-time BOERSE MUENCHEN 07:41:04 2024-05-31 EDT | ||
| 1.13 EUR | 0.00% |
|
| Current month | +197.37% | ||
| 1 month | +197.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.13 | 0.00% |
| 24-05-30 | 1.13 | +7.62% |
| 24-05-29 | 1.05 | -10.26% |
| 24-05-28 | 1.17 | -27.33% |
| 24-05-27 | 1.61 | -1.83% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 07:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HC82TD |
| ISIN | DE000HC82TD8 |
| Date issued | 2023-07-17 |
| Strike | 250 $ |
| Maturity | 2025-06-18 (384 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.65 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.04 € |
| Spread % | 3.54% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151.5
USD
Average target price
138.8
USD
Spread / Average Target
-8.39%
- Stock Market
- Warrants
- Warrant
